Skip to main content
. 2022 Jun 13;12:9753. doi: 10.1038/s41598-022-13102-7

Figure 1.

Figure 1

The clinical efficacy of osimertinib in advanced EGFR-mutant NSCLC patients. (A) The median progression-free survival. (B) The median overall survival. EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer